Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
about
Innovation and access to medicines for neglected populations: could a treaty address a broken pharmaceutical R&D system?Patent and exclusivity status of essential medicines for non-communicable diseasePrices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic AnalysisMaking technological innovation work for sustainable development.Global health equity in United Kingdom university research: a landscape of current policies and practices.Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP).CMV retinitis in China and SE Asia: the way forward.Access to drugs for treatment of noncommunicable diseases.Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality.Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges.Assessing the health impact of transnational corporations: its importance and a framework.Bibliographic review of research publications on access to and use of medicines in low-income and middle-income countries in the Eastern Mediterranean Region: identifying the research gaps.HIV in Africa: Challenges and Directions for the Next Decade.Understanding how domestic health policy is integrated into foreign policy in South Africa: a case for accelerating access to antiretroviral medicines.Mobilising a global response to hepatitis: Lessons learned from the HIV movement.Trade is central to achieving the sustainable development goals: a case study of antimicrobial resistance.Using evidence to drive action: a "revolution in accountability" to implement quality care for better maternal and newborn health in Africa.Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?Estimated generic prices for novel treatments for drug-resistant tuberculosis.'Getting to zero': a steep path ahead.How can the public health community help to invigorate a 'health first' perspective in global drug development debates?Human Rights and the Global Fund to Fight AIDS, Tuberculosis and Malaria: How Does a Large Funder of Basic Health Services Meet the Challenge of Rights-Based Programs?Access to essential medicines for sexual and reproductive health care: the role of the pharmaceutical industry and international regulation.Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.Estimated costs of production and potential prices for the WHO Essential Medicines List.Prevalence of non-communicable diseases and access to care among non-camp Syrian refugees in northern JordanAccess to Medicines in Resource-limited Settings: The End of a Golden Decade?Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations
P2860
Q21144610-F792158E-F51C-4FCC-974F-0BAEA7004D2EQ28485430-307B61B7-4DE5-43FD-A8DA-FA2644F4CC18Q28552507-5F6363F8-3F86-4317-AB11-735B99C24374Q30378608-748A4A8E-AD8F-498F-B5A2-BFCF27DA11CAQ30490160-00122071-4141-49AF-A5E2-FEE6721CB374Q33727955-28204CDB-849E-4B13-837E-7C6123748178Q34083147-D99E5A4C-F05E-4355-9330-7EFC9A8A6DA7Q34916353-EB52DFEF-B085-4853-93F2-16B91A01F203Q36051713-C0145504-FCA8-4262-B48B-1C763167DC57Q36134243-6158E05E-1E2C-4254-8E37-81C81B459300Q36527174-3162AE04-4F32-463E-8291-246A4C24B78DQ36821936-57B4EFAD-058B-4AA8-8681-FE92DB3ABA60Q37006774-323F58A8-52E9-4119-BD26-FAF4BD11D29DQ37228999-E85FF3F8-2A58-41B6-9FCA-3623F188FCEFQ38419599-6A5C40FA-2057-4B0B-A495-9283B8D4C18FQ38689862-660AC3D4-A099-4E52-A115-A28B5429CAF3Q38810895-DFEBD7E2-1FCC-462E-8631-4B12140F8440Q39044433-2EC5A7F7-E8F4-4E54-815B-FAF779EAD924Q39086873-5C344F83-D844-48A4-94E3-7F63BF464129Q40042851-8C24AAD9-D6B2-43F3-958C-3A0A0A9465B1Q40377338-CF2BA4B8-C94C-4ABA-B579-49D552E9C46DQ42655357-99B01351-59ED-4B06-887D-01849607151BQ45781654-980C364F-5B38-44DF-85E8-481616CFEFBEQ47093585-EF9C8768-6F29-4678-B2AF-0DDC3A04B529Q51383722-24C95C98-643C-4FC6-B14F-7DEE3E570CE0Q52659410-123E809F-358E-4CD1-AFC8-D4CC9AFED6BEQ53699577-F7B9D30D-ABB4-48B4-B53E-FBA96F240A56Q56888579-15FF7BF5-3111-4D42-87C1-F8C307A550A0Q56967553-C8347839-BAAF-42C9-9F27-0418C499B505Q58780819-E6C7C831-5EF6-45EF-940B-9278AD4EA2CC
P2860
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
@ast
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
@en
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
@nl
type
label
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
@ast
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
@en
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
@nl
prefLabel
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
@ast
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
@en
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
@nl
P2860
P921
P356
P1476
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
@en
P2093
Jonathan Berger
Suerie Moon
P2860
P2888
P356
10.1186/1758-2652-14-15
P5008
P577
2011-03-27T00:00:00Z
P5875
P6179
1011356632